Xtandi 40 MG capsule 120S
Ended Awarded
- Contract number
- SPE2DB25FZX17
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $8,623
Award facts
- Contract value 100% obligated
- $8,622.72 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $8,622.72 by the Defense Logistics Agency (DLA) on June 5, 2025, for the supply of Xtandi 40 mg capsules (120-count units). The contract, which carries no set-aside designation, is scheduled for ultimate completion by June 6, 2025, with performance taking place at the vendor's Park Ridge facility. This delivery order was issued under DMS Pharmaceutical Group's existing single-award Indefinite Delivery Contract with the DLA under the SPE2DB program, a $499.999 billion contract vehicle valid through November 2026 that enables the agency to procure a comprehensive range of pharmaceutical products supporting military healthcare facilities worldwide.
Xtandi is an oncology medication used in the treatment of prostate cancer, representing one of many specialized pharmaceutical products within DMS Pharmaceutical Group's extensive federal contract portfolio. The vendor has established itself as a crucial supplier within the Department of Defense pharmaceutical supply chain, consistently delivering branded and generic prescription drugs, biologics, and medical consumables to military health facilities. This particular delivery order exemplifies the operational structure of the SPE2DB program, whereby the DLA issues firm fixed-price orders for specific pharmaceutical items to meet the medical supply requirements of its healthcare systems across the globe.
Quick answers
Who was awarded contract SPE2DB25FZX17?
SPE2DB25FZX17 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on June 5, 2025.
How much is contract SPE2DB25FZX17 worth?
The government has obligated $8,623 on SPE2DB25FZX17.
Is contract SPE2DB25FZX17 an order under another contract?
Yes. SPE2DB25FZX17 is a delivery order under SPE2DB20D9135, an indefinite delivery contract.
Was contract SPE2DB25FZX17 competed?
The extent of competition for SPE2DB25FZX17 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award